Mylan rebuffs Teva again; calls bid low, insincere
search

Mylan rebuffs Teva again; calls bid low, insincere

Generic drug company rejects $40.1-billion takeover offer from Israeli pharmaceutical power for second time

The Jerusalem office of the Israeli drug company Teva Pharmaceuticals (Yonatan Sindel/Flash90)
The Jerusalem office of the Israeli drug company Teva Pharmaceuticals (Yonatan Sindel/Flash90)

NEW YORK — Generic drug company Mylan rejected for the second time Monday a $40.1-billion takeover offer from Israeli pharmaceutical power Teva, just days after Mylan’s own bid for rival Perrigo was rebuffed.

Mylan’s board said Teva’s unsolicited offer “grossly undervalues” the company and does not fit its own business strategy.

The Teva proposal first announced on April 21 — and reiterated Friday — “would require Mylan’s shareholders to accept what we believe are low-quality Teva shares in exchange for their high-quality Mylan shares, in a transaction that lacks industrial logic and carries significant global antitrust risk,” the board said.

It also raised doubts about Teva management, saying its leadership team has “a poor record of delivering sustainable shareholder value.”

“We believe that this is only a mere attempt by Teva to frustrate and distract Mylan from its business plan and strategy,” the Mylan board added.

Mylan itself was criticized by smaller generic and over-the-counter drug maker Perrigo on Friday for its hostile $32.6-billion cash-and-shares offer.

Perrigo’s board encouraged shareholders to reject the revised offer as much too low and continued to reject overtures from Mylan to enter talks.

A Teva-Mylan deal would form a $28-billion company, which, according to Teva, could generate $2 billion in annual savings, while expanding its specialty pharmaceutical business.

But Mylan says it believes antitrust regulators would block or stall the deal, disadvantaging shareholders.

A Mylan-Perrigo tie-up would create a company with more than $15 billion in annual sales and generate $800 million in annual savings from operational synergies, according to Mylan.

Mylan shares fell 3.7 percent in opening trade and Teva lost 2.0 percent while Perrigo gained 0.8 percent.

Join us!
A message from the Editor of Times of Israel
David Horovitz

The Times of Israel covers one of the most complicated, and contentious, parts of the world. Determined to keep readers fully informed and enable them to form and flesh out their own opinions, The Times of Israel has gradually established itself as the leading source of independent and fair-minded journalism on Israel, the region and the Jewish world.

We've achieved this by investing ever-greater resources in our journalism while keeping all of the content on our site free.

Unlike many other news sites, we have not put up a paywall. But we would like to invite readers who can afford to do so, and for whom The Times of Israel has become important, to help support our journalism by joining The Times of Israel Community. Join now and for as little as $6 a month you can both help ensure our ongoing investment in quality journalism, and enjoy special status and benefits as a Times of Israel Community member.

Become a member of The Times of Israel Community
read more:
comments